Psoriasis and risk of venous thromboembolism: A systematic review and meta-analysis

QJM: An International Journal of Medicine

Volumn 107, Issue 10, 2014, Pages 793-797

  Ungprasert, Patompong ^a   Sanguankeo, Anawin ^a   Upala, Sikarin ^a   Suksaranjit, Promporn ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); HIGH RISK PATIENT; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PSORIASIS; QUALITY CONTROL; RISK ASSESSMENT; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; COMPLICATION; INFORMATION PROCESSING; OBSERVATIONAL STUDY; ODDS RATIO; STANDARDS;

DATA COLLECTION; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; ODDS RATIO; PSORIASIS; VENOUS THROMBOEMBOLISM;

EID: 84938751565     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcu073     Document Type: Article

References (21)

1. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5:692-9.
2. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep venous thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117:19-25.
3. Heit JA, Silverstein MD, Mohr DN, Petterson PM, O'Fallon WM, Melton LJ III. Predictor of survival after deep venous thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159:445-53.
4. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie 2010; 30:5-6, 8-9.
5. Silvarino R, Danza A, Merola V, Berez A, Mendez E, Espinosa G, et al. Venous thromboembolic disease in systemic autoimmune diseases: an association to keep in mind. Autoimmune Rev 2012; 12:289-94.
6. Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2014; 33:297-304.
7. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2011; 26:314-20.
8. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2013; 2:e000062.
9. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25:603-5.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trial 1986; 7:177-88.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60.
12. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Medicine 2011; 9: 1.
13. Ahlehoff OLE, Gislason GH, Lindhardon J, Charlot MG, Jorgensen CH, Olesen JB, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS ONE 2011; 6:e18125.
14. Lutsey PL, Prizment AE, Folsom AR. Psoriasis is associated with a greater risk of incident venous thromboembolism; the Iowa Women's health study. J Thromb Haemost 2007; 10:708-11.
15. Zoller B, Li X, Sunquist J, Sunquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379:244-9.
16. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009; 48:11-22.
17. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8:5588-92.
18. Brezinski EA, Follanbee MR, Armstrong EJ, Armstrong AW. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 2014; 20:513-29.
19. Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications and perspectives. Curr Rheumatol Rep 2012; 14:343-8.
20. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25:441-6.
21. Bozic-Mijovski M. Hyperhomocysteinemia and thrombophilia. Clin Chem Lab Med 2010; 48(Suppl. 1):S89-95.